- $621.36m
- $603.55m
- $116.59m
Brief: Gyre Therapeutics Inc Files For Shelf Of Up To 1.1 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Gyre Therapeutics Inc Received A Letter From Nasdaq That It Had Regained Compliance With Nasdaq Listing Rule 5605 On March 22
U.S. STOCKS ON THE MOVE-United Airlines, AEON Biopharma, Plug Power
Catalyst Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Catalyst Biosciences Inc expected to post a loss of 7 cents a share - Earnings Preview
Catalyst Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Catalyst Biosciences Inc Notified By Nasdaq That Co Did Not Meet Minimum Bid Price Requirement
Catalyst Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Catalyst Biosciences Inc Says On April 4 Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Catalyst Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: GC Biopharma Says Signs Agreement With Catalyst Biosciences For The Acquisition Of Rare Disease Pipeline In Hematology
U.S. STOCKS ON THE MOVE-Tesla, Virgin Galactic, Warner Bros Discovery
Brief: Catalyst Biosciences Completes First Steps In Reverse Merger Plan
Catalyst Biosciences up on buying fibrosis drug candidate from GNI Group
Catalyst Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Catalyst Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Catalyst Biosciences announces dismissal of JDS1 litigation
Brief: Catalyst Biosciences Reports Q2 2022 Results
Catalyst Biosciences Inc reports results for the quarter ended in June - Earnings Summary